SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

P276-00 (hydrochloride)

Item No. 39845

CAS Registry No.:	920113-03-7
Formal Name:	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one, monohydrochloride
Synonym:	Riviciclib
MF:	$C_{21}H_{20}ClNO_5$ • HCl
FW:	438.3
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

P276-00 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the P276-00 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. P276-00 (hydrochloride) is soluble in acetonitrile and DMSO.

Description

P276-00 is an inhibitor of cyclin-dependent kinase 9 (Cdk9), Cdk4, and Cdk1 (IC_{50}s = 0.020, 0.063, and 0.079 µM, respectively).[1] It is selective for these CDKs over Cdk2/cyclin E, Cdk2/cyclin A, Cdk6, and Cdk7 (IC_{50}s = 2.54, 0.224, 0.396, and 2.87 µM, respectively), as well as a panel of eight other kinases. P276-00 (1 µM) induces apoptosis in HL-60 leukemia cells. It induces cell cycle arrest at the G_1 phase in synchronized H460 non-small cell lung cancer (NSCLC) cells when used at concentrations of 1.5 and 5 µM.[2] P276-00 (50 mg/kg once per day) reduces tumor volume in an H460 mouse xenograft model. It also inhibits reactivation of latent HIV-1 induced by the HIV re-activator prostratin (Item No. 10272), pan-HDAC inhibitor panobinostat (Item No. 13280), or bromodomain inhibitor JQ-1 in 24ST1NLESG cells (IC_{50}s = 0.1, 0.07, and 0.075 µM, respectively).[3]

References

1. Joshi, K.S., Rathos, M.J., Joshi, R.D., *et al. In vitro* antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. *Mol. Cancer Ther.* **6(3)**, 918-925 (2007).
2. Joshi, K.S., Rathos, M.J., Mahajan, P., *et al.* P276-00, a novel cyclin-dependent inhibitor induces G_1-G_2 arrest, shows antitumor activity on cisplatin-resistant cells and significant *in vivo* efficacy in tumor models. *Mol. Cancer Ther.* 6(3), 926-934 (2007).
3. Vargas, B., Giacobbi, N.S., Sanyal, A., *et al.* Inhibitors of signaling pathways that block reversal of HIV-1 latency. *Antimicrob. Agents Chemother.* **63(2)**, e01744-18 (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM